tiprankstipranks
Trending News
More News >
Edgewell Personal Care (EPC)
NYSE:EPC

Edgewell Personal Care (EPC) AI Stock Analysis

Compare
142 Followers

Top Page

EPC

Edgewell Personal Care

(NYSE:EPC)

Select Model
Select Model
Select Model
Neutral 52 (OpenAI - 5.2)
Rating:52Neutral
Price Target:
$22.50
▲(0.45% Upside)
Action:ReiteratedDate:02/09/26
The score is held back primarily by weakening financial performance (profitability and cash flow deterioration) and a high P/E valuation. Technicals are supportive but somewhat overextended, while the latest earnings update was constructive on guidance and strategic focus but still highlighted meaningful near-term margin and demand headwinds.
Positive Factors
Brand portfolio
Edgewell’s deep, diversified brand portfolio across shaving, sun/skin and grooming provides durable retail shelf presence, pricing power and cross‑category distribution. Strong brand equity supports steady revenue access, resilience versus single‑product risk, and multiquarter recovery potential.
Portfolio simplification & deleveraging
Completing the $340M feminine‑care divestiture sharpens strategic focus on core growth categories and provides immediate cash to reduce revolver debt. That structural action lowers leverage, improves capital allocation flexibility and supports execution of margin and reinvestment plans over multiple quarters.
Productivity & international growth
Sustained productivity (240bps) and supply‑chain optimization are structural margin levers that help offset inflation and tariffs. Coupled with international share gains and nearly half of sales abroad, this diversifies growth drivers and supports a multi‑quarter path to improving margins and cash flow.
Negative Factors
Weakened fundamentals
Edgewell’s revenue decline and swing to a TTM net loss, alongside materially reduced operating and free cash flow, weaken the company’s ability to fund investment, dividends or buybacks. Lower cash generation constrains recovery speed and reduces buffer against further cost or demand shocks.
Elevated leverage
A debt/equity ratio near 0.9 is relatively high for a consumer staples business and increases interest and refinancing sensitivity. Elevated leverage restricts strategic optionality, limits M&A capacity, and makes multi‑quarter margin recovery more dependent on cash generation and divestiture proceeds.
Core Wet Shave weakness & promotions
Structural weakness in the Wet Shave category, U.S. consumption declines and elevated promotional intensity pressure volume and margins. Persistently higher promotion and trade investment can erode pricing power and make durable margin improvement harder without sustained market share or product innovation gains.

Edgewell Personal Care (EPC) vs. SPDR S&P 500 ETF (SPY)

Edgewell Personal Care Business Overview & Revenue Model

Company DescriptionEdgewell Personal Care Company, together with its subsidiaries, manufactures and markets personal care products worldwide. It operates through three segments: Wet shave, Sun and Skin care, and Feminine care. The Wet Shave segment provides razor systems, such as razor handles and refillable blades, and disposable shave products for men and women under the Schick, Wilkinson Sword, Edge, Skintimate, Shave Guard, and Personna brands. The Sun and Skin Care segment provides general protection, sport, kids, baby, tanning and after sun products under the Banana Boat and Hawaiian Tropic brands, as well as antibacterial hand wipes, alcohol sanitizing wipes, and hand sanitizer gels under the Wet Ones brand; and skin care products for men under the Bulldog and Jack Black brands, and skin care and grooming products under the Cremo brand. The Feminine Care segment provides tampons under the Playtex Gentle Glide 360°, Playtex Sport, Playtex and o.b. brands; and markets pads and liners under the Stayfree and Carefree brands. The company was formerly known as Energizer Holdings, Inc. and changed its name to Edgewell Personal Care Company in June 2015. Edgewell Personal Care Company was founded in 1772 and is headquartered in Shelton, Connecticut.
How the Company Makes MoneyEdgewell Personal Care generates revenue primarily through the sale of its branded consumer products across multiple categories. The company's key revenue streams include sales from its shaving products, which are a significant portion of its offerings, as well as its sun and skin care products, feminine care products, and infant care products. Edgewell benefits from its established brand recognition and consumer loyalty, which allows it to command premium pricing. Additionally, strategic partnerships with retailers and distributors enhance its market reach and visibility. The company also invests in marketing and product innovation to drive sales growth, adapting to evolving consumer preferences and trends, which further contributes to its overall earnings.

Edgewell Personal Care Earnings Call Summary

Earnings Call Date:Feb 09, 2026
(Q1-2026)
|
% Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Neutral
The call presented a mixed but constructive picture: notable strategic progress (feminine care divestiture completed, proceeds used to reduce debt, strong Sun Care and Grooming growth, 240 bps productivity gains, and international share gains) alongside meaningful near-term challenges (continuing-operations top-line softness, Wet Shave and Skincare declines, Q1 gross margin pressure from inflation/tariffs, GAAP losses, and divestiture-related stranded costs). Management kept FY26 guidance intact for continuing operations, signaled H2 improvement driven by distribution, innovation and pricing, and emphasized a multi-quarter path to margin and cash-flow recovery.
Q1-2026 Updates
Positive Updates
Feminine Care Divestiture Closed
Sale of the feminine care business to Essity closed on Feb 2, 2026; expected annualized benefit to margins and strategy focus; pro forma impact to continuing operations estimated at a $0.44 headwind to adjusted EPS and $44M to adjusted EBITDA in FY2026 (note: normalized 12-month impact would be ~ $0.20 adj EPS / $36M adj EBITDA, better than prior outlook).
Consolidated Results Beat Expectations
On a consolidated basis Q1 organic net sales declined 30 bps but adjusted EPS was $0.30 and adjusted EBITDA was $38M — all modestly ahead of the company's outlook.
Strong Sun Care and Grooming Performance
Sun & Skin Care organic net sales grew ~8% overall; Sun Care grew nearly 20% (driven by ~60% growth in North America due to early retailer orders); Grooming grew ~7% with Cremo +27% and Bulldog +6%.
Productivity Gains and Supply Chain Optimization
Generated ~240 basis points of gross productivity savings in the quarter, on track to support margin expansion and to mitigate tariff/inflation impacts over time.
International Resilience and Market Share Gains
International organic net sales modestly down 1.6% in Q1 (phasing impacts), but company reported share gains across Australia, Europe, Canada and China; international expected to deliver mid-single-digit net sales growth for FY2026 and now represents nearly half of company sales post-divestiture.
Maintained Dividend and Active Capital Allocation
Quarterly dividend declared of $0.15 per share (~$7M returned); proceeds from the feminine care sale directed to debt reduction and strengthening the balance sheet while retaining flexibility for future share repurchases or accretive M&A.
Unchanged FY26 Outlook for Continuing Operations
Management left FY2026 continuing-operations guidance unchanged: organic net sales growth outlook of -1% to +2% (excl. 150 bps currency tailwind), adjusted EBITDA $245M–$265M, adjusted EPS $1.70–$2.10, and adjusted gross margin expected to expand ~60 bps year-over-year.
Negative Updates
Continuing Operations Top-Line Pressure
Continuing operations organic net sales decreased 50 basis points in Q1; Q2 organic sales expected to be down ~3% and first half net sales ~down 2% due to timing/phasing and NPD timing in Japan.
Wet Shave Weakness and Share Pressure in U.S.
Wet Shave organic net sales declined ~4% (NA weaker); U.S. razor & blade category consumption down ~250 bps in the quarter; overall market share declined ~100 bps, with branded value share down ~30 bps despite branded volume share rising 50 bps; core Wet Shave remains the weakest part of the business.
Skincare and Wet Ones Declines
Skincare organic net sales declined ~15%; Wet Ones organic net sales declined ~15% (though roughly flat on a two-year basis), creating notable drag on portfolio growth.
Gross Margin Headwinds; Margin Rate Decline in Q1
Adjusted gross margin rate decreased ~210 basis points in Q1 despite ~240 bps of productivity savings; core inflation, tariffs and volume absorption drove ~450 bps of headwind this quarter.
Profitability and Cash Flow Pressures
Adjusted operating income fell to $8.1M (1.9% of sales) from $15.9M (3.8% prior year); adjusted EPS from continuing operations was a loss of $0.16 (GAAP loss per share from continuing operations $0.63); adjusted EBITDA declined to $25M from $30.9M; net cash used by operating activities worsened to $125.9M (vs $115.6M prior year).
Divestiture-Related Stranded Costs and Transitional Effects
Estimated stranded costs ~ $30M–$35M partially offset by TSA income; FY2026 includes a $44M adjusted EBITDA headwind (net of TSA/interest savings) and ~ $0.44 adj EPS impact, with TSA mitigation phasing through mid-2027 and 18–24 months projected to fully address stranded overhead.
High Promotional Intensity in Shave Category
Promotional competitiveness remains elevated (particularly in women's shave), with management expecting higher-than-typical promotional spending baked into plans and expecting intensity to persist through the season.
Near-Term Margin Phasing and Increased Brand Investment
Management expects first-half gross margin rate to decline vs prior year before returning to growth in H2; A&P to increase ~70 bps to ~12.3% of sales to fund U.S. transformation and brand campaigns, pressuring near-term operating margin (adjusted operating margin expected to decline ~50 bps for FY26).
Company Guidance
Edgewell reiterated its fiscal 2026 continuing‑operations guidance: organic net sales -1% to +2% (ex‑~150 bps currency), with Q2 organic sales ~‑3% and H1 net sales ~‑2%; management expects mid‑single‑digit international growth (resuming in Q2) and to generate ~two‑thirds of adjusted EBITDA in H2. They forecast ~60 bps of full‑year gross‑margin rate accretion (Q2 margin guided to 43–44%) as Q1 productivity of ~240 bps helps offset ~450 bps of core inflation/volume pressure and a net ~$25M tariff headwind; A&P is expected to rise ~70 bps to ~12.3% of sales, driving an adjusted operating‑margin decline of ~50 bps. Full‑year targets include adjusted EBITDA of $245–$265M and adjusted EPS of $1.70–$2.10 (incorporating a $0.44 EPS and $44M EBITDA headwind from the feminine‑care divestiture; normalized annualized divestiture impact ~ $0.20 EPS / $36M EBITDA), adjusted free cash flow (ex‑divestiture) of $80–$110M, and roughly 85% of adjusted EPS realized in H2; capex is near its peak and proceeds from the divestiture will be used primarily to reduce debt.

Edgewell Personal Care Financial Statement Overview

Summary
Fundamentals have deteriorated: revenue is flat-to-down, profitability compressed sharply with a TTM net loss, and operating/free cash flow are materially lower vs FY2023–FY2024. The balance sheet is stable but moderately leveraged (debt-to-equity ~0.9) and returns on equity have weakened.
Income Statement
44
Neutral
Results have weakened materially versus prior years. Revenue is down slightly in both FY2025 (annual) and 2025 TTM (Trailing-Twelve-Months), and profitability has compressed sharply: net income swung to a loss in TTM after solid profits in FY2021–FY2024. While gross margin has held relatively steady (~41–42% recently), operating margins (EBIT/EBITDA) are meaningfully lower than FY2023–FY2024 levels, indicating higher costs and/or weaker operating leverage.
Balance Sheet
58
Neutral
Leverage looks manageable but not conservative. Debt-to-equity sits around ~0.9 across periods, suggesting a fairly leveraged capital structure for a consumer products company, though equity remains sizable (~$1.5B) and assets are stable (~$3.7B). Returns on equity have deteriorated significantly in FY2025 and TTM versus FY2023–FY2024, reflecting the earnings compression and reducing balance-sheet quality from a shareholder return perspective.
Cash Flow
46
Neutral
Cash generation has cooled meaningfully. Operating cash flow and free cash flow are much lower in FY2025 and 2025 TTM (Trailing-Twelve-Months) versus FY2023–FY2024, and free cash flow growth is negative in the most recent periods. Cash conversion versus accounting earnings is also weaker than in prior years, and while free cash flow remains positive, the reduced level provides less cushion for debt service, buybacks, or reinvestment.
BreakdownTTMSep 2025Sep 2024Sep 2023Sep 2022Sep 2021
Income Statement
Total Revenue2.17B2.22B2.25B2.25B2.17B2.09B
Gross Profit894.30M924.90M955.70M940.80M880.50M951.20M
EBITDA150.50M185.60M285.40M317.60M285.40M302.10M
Net Income-38.20M25.40M98.60M114.70M99.50M117.80M
Balance Sheet
Total Assets3.77B3.76B3.73B3.74B3.71B3.67B
Cash, Cash Equivalents and Short-Term Investments223.30M225.70M209.10M216.40M188.70M479.20M
Total Debt1.55B1.54B1.39B1.45B1.46B1.32B
Total Liabilities2.28B2.20B2.15B2.20B2.25B2.09B
Stockholders Equity1.49B1.55B1.58B1.54B1.47B1.58B
Cash Flow
Free Cash Flow36.30M41.40M174.50M166.60M45.60M172.20M
Operating Cash Flow108.10M118.40M231.00M216.10M102.00M229.00M
Investing Cash Flow-67.10M-72.90M-62.40M-50.50M-355.40M-48.70M
Financing Cash Flow-6.50M-30.00M-179.40M-146.50M-17.60M-65.40M

Edgewell Personal Care Technical Analysis

Technical Analysis Sentiment
Positive
Last Price22.40
Price Trends
50DMA
19.07
Positive
100DMA
18.86
Positive
200DMA
21.45
Positive
Market Momentum
MACD
1.02
Negative
RSI
72.75
Negative
STOCH
91.12
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EPC, the sentiment is Positive. The current price of 22.4 is above the 20-day moving average (MA) of 20.79, above the 50-day MA of 19.07, and above the 200-day MA of 21.45, indicating a bullish trend. The MACD of 1.02 indicates Negative momentum. The RSI at 72.75 is Negative, neither overbought nor oversold. The STOCH value of 91.12 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EPC.

Edgewell Personal Care Risk Analysis

Edgewell Personal Care disclosed 28 risk factors in its most recent earnings report. Edgewell Personal Care reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Edgewell Personal Care Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
$24.87B34.8417.62%1.38%1.45%42.04%
68
Neutral
$1.81B18.315.34%3.15%-5.21%1.96%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
61
Neutral
$36.88B18.32147.22%5.03%-10.04%-23.41%
52
Neutral
$1.05B-26.441.62%3.51%-1.34%-73.59%
51
Neutral
$2.35B-4.26-14.50%-5.68%-358.36%
49
Neutral
$1.93B-6.69-11.09%7.76%-5.88%90.23%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
EPC
Edgewell Personal Care
22.40
-8.21
-26.82%
CHD
Church & Dwight
103.63
-3.56
-3.33%
KMB
Kimberly Clark
109.21
-24.48
-18.31%
NWL
Newell Brands
4.56
-1.74
-27.61%
SPB
Spectrum Brands Holdings
77.53
0.52
0.68%
COTY
Coty
2.65
-3.12
-54.07%

Edgewell Personal Care Corporate Events

Business Operations and StrategyFinancial DisclosuresM&A TransactionsShareholder Meetings
Edgewell Reaffirms Outlook After Feminine Care Divestiture
Positive
Feb 9, 2026

At its February 5, 2026 annual meeting, Edgewell shareholders approved the company’s 3rd Amended and Restated 2018 Stock Incentive Plan, adding 2.1 million authorized shares, removing the fungible share ratio for new awards, and updating provisions in light of U.S. tax code changes. Investors also re-elected the full slate of directors, ratified PricewaterhouseCoopers as auditor for fiscal 2026, and backed the advisory vote on executive pay, underscoring broad support for management and its compensation and governance framework.

On February 9, 2026, Edgewell reported first-quarter fiscal 2026 results modestly ahead of its expectations for sales, adjusted EPS and EBITDA and confirmed its full-year outlook for continuing operations after completing the $340 million divestiture of its Feminine Care business. While revenue grew slightly and currency provided a tailwind, margins and earnings remained pressured by inflation, restructuring charges and higher interest costs, even as the company signaled a more focused portfolio and balance-sheet strengthening that it believes position it for sustainable growth and shareholder returns.

The most recent analyst rating on (EPC) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on Edgewell Personal Care stock, see the EPC Stock Forecast page.

Business Operations and StrategyFinancial DisclosuresM&A Transactions
Edgewell Completes Feminine Care Divestiture to Essity
Positive
Feb 6, 2026

On February 2, 2026, Edgewell Personal Care completed the previously announced sale of its Feminine Care business to Swedish health and hygiene group Essity for approximately $340 million in cash, transferring specified assets and liabilities under an asset purchase agreement first signed in November 2025. Edgewell plans to use the net proceeds, after taxes and transaction costs, primarily to strengthen its balance sheet by paying down its U.S. revolving credit facility and to continue investing in the long-term growth of its core shave, sun and skin care, and grooming franchises, a shift management describes as a pivotal step in simplifying the portfolio and sharpening strategic focus; the company has also entered a transition services agreement with Essity for at least one year to support accounting, IT, quality, operations, supply chain and sales, and will reclassify the divested unit as a discontinued operation in upcoming pro forma financial disclosures to investors.

The most recent analyst rating on (EPC) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Edgewell Personal Care stock, see the EPC Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 09, 2026